Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

293 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Association of Neutralizing Antispike Monoclonal Antibody Treatment With Coronavirus Disease 2019 Hospitalization and Assessment of the Monoclonal Antibody Screening Score.
Johnson PW, Kunze KL, Senefeld JW, Sinclair JE, Isha S, Satashia PH, Bhakta S, Cowart JB, Bosch W, O'Horo J, Shah SZ, Wadei HM, Edwards MA, Pollock BD, Edwards AJ, Scheitel-Tulledge S, Clune CG, Hanson SN, Arndt R, Heyliger A, Kudrna C, Bierle DM, Buckmeier JR, Seville MTA, Orenstein R, Libertin C, Ganesh R, Franco PM, Razonable RR, Carter RE, Sanghavi DK, Speicher LL. Johnson PW, et al. Among authors: arndt r. Mayo Clin Proc Innov Qual Outcomes. 2023 Apr;7(2):109-121. doi: 10.1016/j.mayocpiqo.2022.12.007. Epub 2023 Jan 11. Mayo Clin Proc Innov Qual Outcomes. 2023. PMID: 36644593 Free PMC article.
A Framework for Outpatient Infusion of Antispike Monoclonal Antibodies to High-Risk Patients with Mild-to-Moderate Coronavirus Disease-19: The Mayo Clinic Model.
Razonable RR, Aloia NCE, Anderson RJ, Anil G, Arndt LL, Arndt RF, Ausman SE, Bell SJ, Bierle DM, Billings ML, Bishop RK, Cramer CH, Culbertson TL, Dababneh AS, Derr AN, Epps K, Flaker SM, Ganesh R, Gilmer MA, Urena EG, Gulden CR, Haack TL, Hanson SN, Herzog JR, Heyliger A, Hokanson LD, Hopkins LH, Horecki RJ, Krishna BH, Huskins WC, Jackson TA, Johnson RR, Jorgenson B, Kudrna C, Kennedy BD, Klingsporn MK, Kottke B, Larsen JJ, Lessard SR, Lutwick LI, Malone EJ 3rd, Matoush JA, Micallef IN, Moehnke DE, Mohamed M, Ness CN, Olson SM, Orenstein R, Palraj R, Patel J, Paulson DJ, Phelan D, Peinovich MT, Ramsey WL, Rau-Kane TJ, Reid KI, Reinschmidt KJ, Seville MT, Skold EC, Smith JM, Speicher LL, Spielman LA, Springer DJ, Sweeten PW, Tempelis JM, Tulledge-Scheitel S, Vergidis P, Whipple DC, Wilker CG, Destro Borgen MJ. Razonable RR, et al. Among authors: arndt ll, arndt rf. Mayo Clin Proc. 2021 May;96(5):1250-1261. doi: 10.1016/j.mayocp.2021.03.010. Epub 2021 Mar 9. Mayo Clin Proc. 2021. PMID: 33958056 Free PMC article.
Association of Intravenous Bamlanivimab Use with Reduced Hospitalization, Intensive Care Unit Admission, and Mortality in Patients with Mild to Moderate COVID-19.
Ganesh R, Pawlowski C, O'Horo JC, Arndt LL, Arndt R, Bell SJ, Bierle DM, Borgen MD, Hanson SN, Heyliger A, Larsen JJ, Lenehan P, Orenstein R, Puranik A, Speicher LL, Tulledge-Scheitel SM, Venkatakrishnan AJ, Wilker CG, Badley AD, Razonable RR. Ganesh R, et al. Among authors: arndt ll, arndt r. medRxiv [Preprint]. 2021 May 25:2021.05.23.21257670. doi: 10.1101/2021.05.23.21257670. medRxiv. 2021. Update in: J Clin Invest. 2021 Oct 1;131(19):e151697. doi: 10.1172/JCI151697 PMID: 34075387 Free PMC article. Updated. Preprint.
Real-World Clinical Outcomes of Bamlanivimab and Casirivimab-Imdevimab Among High-Risk Patients With Mild to Moderate Coronavirus Disease 2019.
Ganesh R, Philpot LM, Bierle DM, Anderson RJ, Arndt LL, Arndt RF, Culbertson TL, Destro Borgen MJ, Hanson SN, Kennedy BD, Kottke BB, Larsen JJ, Ramar P, Rosedahl JK, Seville MT, Speicher LL, Tulledge-Scheitel SM, Wilker CG, Razonable RR. Ganesh R, et al. Among authors: arndt ll, arndt rf. J Infect Dis. 2021 Oct 28;224(8):1278-1286. doi: 10.1093/infdis/jiab377. J Infect Dis. 2021. PMID: 34279629 Free PMC article.
Intravenous bamlanivimab use associates with reduced hospitalization in high-risk patients with mild to moderate COVID-19.
Ganesh R, Pawlowski CF, O'Horo JC, Arndt LL, Arndt RF, Bell SJ, Bierle DM, Borgen MD, Hanson SN, Heyliger A, Larsen JJ, Lenehan PJ, Orenstein R, Puranik A, Speicher LL, Tulledge-Scheitel SM, Venkatakrishnan AJ, Wilker CG, Badley AD, Razonable RR. Ganesh R, et al. Among authors: arndt ll, arndt rf. J Clin Invest. 2021 Oct 1;131(19):e151697. doi: 10.1172/JCI151697. J Clin Invest. 2021. PMID: 34411003 Free PMC article.
Casirivimab-Imdevimab treatment is associated with reduced rates of hospitalization among high-risk patients with mild to moderate coronavirus disease-19.
Razonable RR, Pawlowski C, O'Horo JC, Arndt LL, Arndt R, Bierle DM, Borgen MD, Hanson SN, Hedin MC, Lenehan P, Puranik A, Seville MT, Speicher LL, Tulledge-Scheitel SM, Venkatakrishnan AJ, Wilker CG, Badley AD, Ganesh R. Razonable RR, et al. Among authors: arndt ll, arndt r. EClinicalMedicine. 2021 Oct;40:101102. doi: 10.1016/j.eclinm.2021.101102. Epub 2021 Aug 30. EClinicalMedicine. 2021. PMID: 34485873 Free PMC article.
Effectiveness of Monoclonal Antibodies in Preventing Severe COVID-19 With Emergence of the Delta Variant.
O'Horo JC, Challener DW, Speicher L, Bosch W, Seville MT, Bierle DM, Ganesh R, Wilker CG, Arndt RF, Arndt LL, Tulledge-Scheitel SM, Hanson SN, Razonable RR. O'Horo JC, et al. Among authors: arndt ll, arndt rf. Mayo Clin Proc. 2022 Feb;97(2):327-332. doi: 10.1016/j.mayocp.2021.12.002. Epub 2021 Dec 16. Mayo Clin Proc. 2022. PMID: 35120695 Free PMC article.
Rates of Severe Outcomes After Bamlanivimab-Etesevimab and Casirivimab-Imdevimab Treatment of High-Risk Patients With Mild to Moderate Coronavirus Disease 2019.
O'Horo J, Challener DW, Anderson RJ, Arndt RF, Ausman SE, Hall ST, Heyliger A, Kennedy BD, Sweeten PW, Ganesh R, Razonable RR. O'Horo J, et al. Among authors: arndt rf. Mayo Clin Proc. 2022 May;97(5):943-950. doi: 10.1016/j.mayocp.2022.02.009. Epub 2022 Feb 23. Mayo Clin Proc. 2022. PMID: 35512884 Free PMC article.
Curbing the Delta Surge: Clinical Outcomes After Treatment With Bamlanivimab-Etesevimab, Casirivimab-Imdevimab, or Sotrovimab for Mild to Moderate Coronavirus Disease 2019.
Razonable RR, O'Horo JC, Challener DW, Arndt L, Arndt RF, Clune CG, Culbertson TL, Hall ST, Heyliger A, Jackson TA, Kennedy BD, Larsen J, Hanson SN, Sweeten PW, Tulledge-Scheitel SM, Ganesh R. Razonable RR, et al. Among authors: arndt rf, arndt l. Mayo Clin Proc. 2022 Sep;97(9):1641-1648. doi: 10.1016/j.mayocp.2022.06.015. Epub 2022 Jun 23. Mayo Clin Proc. 2022. PMID: 36058578 Free PMC article.
Comparable Outcomes for Bebtelovimab and Ritonavir-Boosted Nirmatrelvir Treatment in High-Risk Patients With Coronavirus Disease-2019 During Severe Acute Respiratory Syndrome Coronavirus 2 BA.2 Omicron Epoch.
Razonable RR, O'Horo JC, Hanson SN, Arndt RF, Speicher LL, Seville TA, Hall ST, Pike ML, Heyliger A, Larsen JJ, Ganesh R, Tulledge-Scheitel SM. Razonable RR, et al. Among authors: arndt rf. J Infect Dis. 2022 Nov 11;226(10):1683-1687. doi: 10.1093/infdis/jiac346. J Infect Dis. 2022. PMID: 36124696 Free PMC article.
293 results